Oncodesign Announces the Third Extension of a Research Contract with Isarna Therapeutics

Regulatory News :

ONCODESIGN (Paris:ALONC) (FR0011766229 - ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, announced today the signing of an agreement with Isarna Therapeutics GmbH. Oncodesign will conduct in vivo pharmacology studies to investigate the potential of TGF-ß therapeutics that stimulate the human immune system to effectively fight cancer, ocular diseases and fibrosis.

The total TGF-ß therapeutics development program represents 1.75 M Euros of revenues for Oncodesign, of which 0.25 M Euros will be received for the third extension. The renewal extends the current agreement through the end of calendar year 2014 and includes Oncodesign scientific and technical support to Isarna Therapeutics’ oncology research.

Philippe Genne, Chairman and CEO of Oncodesign, commented, "We have devised relevant solutions to predict the potential efficacy of anti-cancer molecules from major biotechnology and pharmaceutical companies. Today, with more than 3,000 therapeutic molecules tested, more than 500 clients and the unique experience we have acquired, we are continuing to take our mission a step further as we accompany our clients in long-term research contracts. We are very appreciative to get the trust of Isarna Therapeutics for the third time and to further contribute to the TGF-ß therapeutics development.”

"Isarna has established an exciting pipeline of TGF-ß-focused compounds targeted to treat diseases of the eye and fibrosis as well as cancer indications,” said Dr. Philippe Calais, CEO of Isarna. "Our partnership with Oncodesign has enabled us to incorporate a high level of value into the timely development of our pipeline.”

About Isarna Therapeutics: www.isarna-therapeutics.com
Isarna Therapeutics has an unmatched commitment to developing selective TGF-ß inhibitors to fight cancer and to effectively treat ophthalmic and fibrotic diseases. We are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

About ONCODESIGN: www.oncodesign.com
Founded 19 years ago by Dr. Philippe Genne, the Company’s CEO and majority shareholder, ONCODESIGN is a biotechnology company that maximizes the pharmaceutical industry’s chances of success in discovering new therapeutic molecules to fight cancer and other serious illnesses with no known efficient treatment. Backed by unique experience acquired through more than 500 clients, including the world’s largest pharmaceutical companies, and relying on a comprehensive technological platform combining state-of-the-art medicinal chemistry, advanced animal modeling and medical imaging, ONCODESIGN is able to predict and identify for every molecule, very upstream, its therapeutic use and its potential to become an efficient drug. Applied to kinase inhibitors, molecules that represent a market estimated at over 40 billion dollars in 2016 and accounting for almost 25% of the pharmaceutical industry’s R&D investments, ONCODESIGN’s technology has already enabled the targeting of 7 promising molecules with substantial therapeutic potential, in oncology and elsewhere, and the signing of partnerships, potentially worth €350 million in upfront payments should predefined milestones be reached, with pharmaceutical groups Sanofi, Ipsen and UCB. Based in Dijon, France, in the heart of the town’s university and hospital hub, ONCODESIGN has 63 staff.